Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Calvez

Showing results (121-130 of 141) with videos related to

Pageof 15
Sort By:
Annals of Internal Medicine|October 3, 1998
Efficacy and tolerability of stavudine plus lamivudine in treatment-naive and treatment-experienced patients with HIV-1 infectionC Katlama, M A Valantin, S Matheron, et al.
AIDS Research and Human Retroviruses|January 12, 2001
HIV RNA and HIV DNA in peripheral blood mononuclear cells are consistent markers for estimating viral load in patients undergoing long-term potent treatmentM Burgard, J Izopet, B Dumon, et al.
The Journal of Antimicrobial Chemotherapy|July 10, 2020
Persistent low-level viraemia in antiretroviral treatment-experienced patients is not linked to viral resistance or inadequate drug concentrationsR Palich, M Wirden, G Peytavin, et al.
Pathologie-Biologie|August 19, 2000
[Conditions of "thymidine analog mutations" (TAMs) in naive patients treated with different combinations of d4T]M Mouroux, J Izopet, D Descamps, et al.
Antimicrobial Agents and Chemotherapy|May 17, 2001
Genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 variants with insertions or deletions in the reverse transcriptase (RT): multicenter study of patients treated with RT inhibitorsB Masquelier, E Race, C Tamalet, et al.
Archives of Dermatology|December 15, 2000
Clinical features and contribution of virological findings to the management of Kaposi sarcoma in organ-allograft recipientsS Barete, V Calvez, C Mouquet, et al.
The Journal of Antimicrobial Chemotherapy|July 25, 2014
Rapid plasma viral suppression in naive HIV-infected patients with high CD4 cells and low viraemia initiating a dual nucleoside reverse transcriptase inhibitor strategy: a proof-of-concept studyS Seang, S Fourati, Y Keita, et al.
Antiviral Therapy|January 26, 2002
Low-rate emergence of thymidine analogue mutations and multi-drug resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus lamivudine combination therapyM Mouroux, D Descamps, J Izopet, et al.
The Journal of Antimicrobial Chemotherapy|January 31, 2013
Prevalence of pre-existing resistance-associated mutations to rilpivirine, emtricitabine and tenofovir in antiretroviral-naive patients infected with B and non-B subtype HIV-1 virusesS Lambert-Niclot, C Charpentier, A Storto, et al.
The Journal of Antimicrobial Chemotherapy|November 28, 2008
High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patientsD Rey, B Hoen, P Chavanet, et al.
Pageof 15

Showing results (121-130 of 141) with videos related to

Sort By:
Pageof 15
Annals of Internal Medicine|October 3, 1998
Efficacy and tolerability of stavudine plus lamivudine in treatment-naive and treatment-experienced patients with HIV-1 infectionC Katlama, M A Valantin, S Matheron, et al.
AIDS Research and Human Retroviruses|January 12, 2001
HIV RNA and HIV DNA in peripheral blood mononuclear cells are consistent markers for estimating viral load in patients undergoing long-term potent treatmentM Burgard, J Izopet, B Dumon, et al.
The Journal of Antimicrobial Chemotherapy|July 10, 2020
Persistent low-level viraemia in antiretroviral treatment-experienced patients is not linked to viral resistance or inadequate drug concentrationsR Palich, M Wirden, G Peytavin, et al.
Pathologie-Biologie|August 19, 2000
[Conditions of "thymidine analog mutations" (TAMs) in naive patients treated with different combinations of d4T]M Mouroux, J Izopet, D Descamps, et al.
Antimicrobial Agents and Chemotherapy|May 17, 2001
Genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 variants with insertions or deletions in the reverse transcriptase (RT): multicenter study of patients treated with RT inhibitorsB Masquelier, E Race, C Tamalet, et al.
Archives of Dermatology|December 15, 2000
Clinical features and contribution of virological findings to the management of Kaposi sarcoma in organ-allograft recipientsS Barete, V Calvez, C Mouquet, et al.
The Journal of Antimicrobial Chemotherapy|July 25, 2014
Rapid plasma viral suppression in naive HIV-infected patients with high CD4 cells and low viraemia initiating a dual nucleoside reverse transcriptase inhibitor strategy: a proof-of-concept studyS Seang, S Fourati, Y Keita, et al.
Antiviral Therapy|January 26, 2002
Low-rate emergence of thymidine analogue mutations and multi-drug resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus lamivudine combination therapyM Mouroux, D Descamps, J Izopet, et al.
The Journal of Antimicrobial Chemotherapy|January 31, 2013
Prevalence of pre-existing resistance-associated mutations to rilpivirine, emtricitabine and tenofovir in antiretroviral-naive patients infected with B and non-B subtype HIV-1 virusesS Lambert-Niclot, C Charpentier, A Storto, et al.
The Journal of Antimicrobial Chemotherapy|November 28, 2008
High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patientsD Rey, B Hoen, P Chavanet, et al.
Pageof 15